Biblio

Found 364 results
Author Keyword Title Type [ Year(Asc)]
2020
X. Paoletti, Lewsley, L. - A., Daniele, G., Cook, A., Yanaihara, N., Tinker, A., Kristensen, G., Ottevanger, P. B., Aravantinos, G., Miller, A., Boere, I. A., Fruscio, R., Reyners, A. K. L., Pujade-Lauraine, E., Harkin, A., Pignata, S., Kagimura, T., Welch, S., Paul, J., Karamouza, E., and Glasspool, R. M., Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis., JAMA Netw Open, vol. 3, no. 1, p. e1918939, 2020.
W. Small, Peltecu, G., Puiu, A., Corha, A., Cocîrṭă, E., Cigăran, R. Gabriela, Plante, M., Jhingran, A., Stang, K., Gaffney, D., Bacon, M., and McCormack, M., Cervical cancer in Eastern Europe: review and proceedings from the Cervical Cancer Research Conference., Int J Gynecol Cancer, 2020.
I. Rohr, Alavi, S., Richter, R., Keller, M., Chekerov, R., Oskay-Özcelik, G., Heinrich, M., Taskiran, C., Joly, F., Berger, R., Bois, Adu, Gornjec, A., Vergote, I., Achimas-Cadariu, P., Lorusso, D., Maenpaa, J., and Sehouli, J., Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV)., Int J Gynecol Cancer, vol. 30, no. 4, pp. 509-514, 2020.
F. Falcone, Maggiore, U. Leone Robe, Di Donato, V., Perrone, A. Myriam, Frigerio, L., Bifulco, G., Polterauer, S., Casadio, P., Cormio, G., Masciullo, V., Malzoni, M., and Greggi, S., Fertility-sparing treatment for intramucous, moderately differentiated, endometrioid endometrial cancer: a Gynecologic Cancer Inter-Group (GCIG) study, Journal of Gynecologic Oncology, vol. 31, 2020.
2018
S. M. de Boer, Powell, M. E., Mileshkin, L. R., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. - H., Jürgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D. M., Hanzen, C., Lutgens, L. C. H. W., Smit, V. T. H. B. M., Singh, N., Do, V., D'Amico, R., Nout, R. A., Feeney, A., Verhoeven-Adema, K. W., Putter, H., and Creutzberg, C. L., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial., Lancet Oncol, 2018.
S. C. Dowdy and Glaser, G. E., Adjuvant therapy for women with high-risk endometrial carcinoma., Lancet Oncol, 2018.
V. D. Gonzalez, Samusik, N., Chen, T. J., Savig, E. S., Aghaeepour, N., Quigley, D. A., Huang, Y. - W., Giangarrà, V., Borowsky, A. D., Hubbard, N. E., Chen, S. - Y., Han, G., Ashworth, A., Kipps, T. J., Berek, J. S., Nolan, G. P., and Fantl, W. J., Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry., Cell Rep, vol. 22, no. 7, pp. 1875-1888, 2018.
M. Leonard Friedlander, Rau, J., Lee, C. Khoon, Meier, W., Lesoin, A., Kim, J. - W., Poveda, A. M., Buck, M., Scambia, G., Shimada, M., Hilpert, F., King, M. Trudy, Debruyne, P., Bologna, A., Malander, S., Monk, B. J., Petru, E., Calvert, P., Herzog, T. J., Barrett, C., and A Bois, du, Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial., Ann Oncol, vol. 29, no. 3, pp. 737-743, 2018.
D. K. Gaffney, Hashibe, M., Kepka, D., Maurer, K. A., and Werner, T. L., Too many women are dying from cervix cancer: Problems and solutions., Gynecol Oncol, 2018.
2016
S. Sagae, Monk, B. J., Pujade-Lauraine, E., Gaffney, D. K., Narayan, K., Ryu, S. Young, McCormack, M., Plante, M., Casado, A., Reuss, A., Chávez-Blanco, A., Kitchener, H. C., Nam, B. - H., Jhingran, A., Temkin, S., Mileshkin, L. R., Berns, E. M. J. J., Scholl, S., Doll, C., Abu-Rustum, N. R., Lecuru, F., and Small, W., Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future., Int J Gynecol Cancer, vol. 26, no. 1, p. 207, 2016.
P. Harter, Johnson, T., Berton-Rigaud, D., Park, S. - Y., Friedlander, M. Leonard, Del Campo, J. M., Shimada, M., Forget, F., Mirza, M. R., Colombo, N., Zamagni, C., Chan, J. K., Imhof, M., Herzog, T. J., O'Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., Jobanputra, M., Xu, C. - F., and du Bois, A., BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study., Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.
J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M. Leonard, Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A. D., Kaplan, R. S., and Parmar, M. K. B., Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.
D. J. Pulford, Harter, P., Floquet, A., Barrett, C., Suh, D. Hoon, Friedlander, M. Leonard, Arranz, J. Angel, Hasegawa, K., Tada, H., Vuylsteke, P., Mirza, M. R., Donadello, N., Scambia, G., Johnson, T., Cox, C., Chan, J. K., Imhof, M., Herzog, T. J., Calvert, P., Wimberger, P., Berton-Rigaud, D., Lim, M. Cheol, Elser, G., Xu, C. - F., and Bois, Adu, Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study., BMC Med Ethics, vol. 17, no. 1, p. 63, 2016.
A. M. Angarita, Johnson, C. Alonia Lil, Fader, A. Nickles, and Christianson, M. S., Fertility preservation: A key survivorship issue for young women with cancer , Frontiers in Oncology , vol. 6, no. 102, 2016.
S. Lheureux, Karakasis, K., Harter, P., Scott, C., Bacon, M., Bryce, J., Le Fur, N., Pujade-Lauraine, E., and Oza, A. M., Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions., Gynecol Oncol, vol. 140, no. 1, p. 94, 2016.
K. Katherine, Julia, B., Valerie, B., Oza, A. M., and Stephanie, L., Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention , Frontiers in Oncology , vol. 6, no. 00119 , 2016.
Y. Ikeda, Furusawa, A., Kitagawa, R., Tokinaga, A., Ito, F., Ukita, M., Nomura, H., Yamagami, W., Tanabe, H., Mikami, M., Takeshima, N., and Yaegashi, N., Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan., J Gynecol Oncol, vol. 27, no. 3, p. e29, 2016.
K. Harano, Hirakawa, A., Yunokawa, M., Nakamura, T., Satoh, T., Nishikawa, T., Aoki, D., Ito, K., Ito, K., Nakanishi, T., Susumu, N., Takehara, K., Watanabe, Y., Watari, H., and Saito, T., Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group., Int J Clin Oncol, vol. 21, no. 1, pp. 168-76, 2016.
L. Brotto, Brundage, M., Hoskins, P., Vergote, I. B., Cervantes, A., Casado, H. A., Poveda, A. M., Eisenhauer, E., and Tu, D., Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life., Support Care Cancer, vol. 24, no. 3, p. 1249, 2016.
S. Temkin, Tanner, E. J., Dewdney, S., and Minasian, L. M., Reducing overtreatment in gynecologic oncology: the case for less in endometrial and ovarian cancer, Frontiers in Oncology , vol. 6, no. 00118 , 2016.

Pages